Q-Line Biotech LimitedQLINECorporate

Latest results: Sep 2026 1 quarters of data

—

MCap —

Live price not available

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹152 Cr

Sales · Sep 2026

₹40 Cr

Operating Profit · Sep 2026

26.0%

OPM % · Sep 2026

₹20 Cr

Net Profit · Sep 2026

₹10.47

EPS · Sep 2026

📝 Q-Line Biotech Limited — results explained

Quarter ended September 2026 (Q2 FY27)

Q-Line Biotech Limited reported revenue of ₹152 crore for the quarter ended September 2026 (Q2 FY27).

Net profit stood at ₹20 crore. Earnings per share (EPS) came in at ₹10.47.

Operating profit stood at ₹40 crore — an operating margin (OPM) of 26.0%.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

N/A

Current Price ?

N/A

P/E ?

N/A

Industry P/E ?

N/A

P/B ?

N/A

P/S ?

N/A

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

N/A

Profitability & Returns

Sales (TTM) ?

N/A

OPM ?

N/A

Profit after tax (TTM) ?

N/A

EPS (TTM) ?

N/A

ROCE ?

N/A

ROE ?

N/A

ROA ?

N/A

Growth

Sales — latest qtr ?

₹152 Cr

PAT — latest qtr ?

₹20 Cr

YoY qtr sales growth ?

N/A

YoY qtr profit growth ?

N/A

Sales growth (3y) ?

N/A

Sales growth (5y) ?

N/A

Profit growth (3y) ?

N/A

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹132 Cr

Debt to Equity ?

0.27

Interest Coverage ?

N/A

Ownership

Promoter holding ?

N/A

Change in promoter holding ?

N/A

FII holding ?

N/A

DII holding ?

N/A

Market

Return 3 months ?

N/A

Return 6 months ?

N/A

🗓️ Quarterly results (1 quarters · ₹ Cr)

same fiscal quarter as Sep bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2026	YoY %	QoQ %
Sales	152	—	—
Operating Profit	40	—	—
Other Income	4	—	—
Interest	10	—	—
Depreciation	8	—	—
Profit Before Tax	26	—	—
Net Profit	20	—	—
EPS	10.47	—	—
OPM %	26.0%	—	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 1 periods)

Metric	Sep 2026	% Chg
Equity Capital	23	—
Reserves	458	—
Borrowings	132	—
Other Liabilities	76	—
Total Liabilities	690	—
Fixed Assets	141	—
CWIP	20	—
Investments	18	—
Other Assets	511	—
Total Assets	690	—

📦 Working Capital (latest 1 periods)

Metric	Sep 2026	% Chg
Inventories	108	—
Trade Receivables	138	—
Trade Payables	38	—

💧 Half-year Cash Flow (latest 1 periods)

Metric	Sep 2026	% Chg
Cash from Operating Activity	-9	—
Cash from Investing Activity	-111	—
Cash from Financing Activity	112	—
Net Cash Flow	-8	—

⚖️ Peer comparison

Peer comparison unavailablePeer comparison unavailable — industry and sector are not classified for this symbol.

❓ Frequently asked questions

What was Q-Line Biotech Limited's revenue in Q2 FY27?